Evidence map›Paper›PMID 34621058›Full record

ReviewNature reviews. Nephrology2022

Opioids for chronic pain management in patients with dialysis-dependent kidney failure.

Daniel G Tobin, Mark B Lockwood, Paul L Kimmel, Laura M Dember, Nwamaka D Eneanya, Manisha Jhamb, Thomas D Nolin, William C Becker, Michael J Fischer, HOPE Consortium

Open access · greenAbstract readReview
In one paragraph

Review in Nature reviews. Nephrology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 1 pooled it
6.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. A Fentanyl-Responsive Microneedle Patch for Harm Reduction.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 1 country.

Daniel G TobinDepartment of Internal Medicine, Yale School of Medicine, New Haven, CT, USA. daniel.tobin@yale.edu.ORCID http://orcid.org/0000-0002-4572-8965
Mark B LockwoodDepartment of Behavioral Health Science, University of Illinois at Chicago, College of Nursing, Chicago, IL, USA.ORCID http://orcid.org/0000-0003-2534-8583
Paul L KimmelDivision of Renal Diseases and Hypertension, The George Washington University, Washington, WA, USA.
Laura M DemberDivision of Renal-Electrolyte and Hypertension, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0002-9735-7473
Nwamaka D EneanyaDivision of Renal-Electrolyte and Hypertension, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Manisha JhambDivision of Renal-Electrolyte, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Thomas D NolinDivision of Renal-Electrolyte, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.ORCID http://orcid.org/0000-0003-4339-1382
William C Becker *Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.
Michael J Fischer *Department of Internal Medicine, University of Illinois Hospital and Health Sciences Center, Chicago, IL, USA.
HOPE Consortium
University of Pennsylvania · USUniversity of Pittsburgh · USYale University · USEdward Hines, Jr. VA Hospital · USGeorge Washington University · USUniversity of Illinois Chicago · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
UPENN Scientific and Data Research Center for the HOPE Consortium to Reduce Pain and Opioid Use in Hemodialysis U01DK123813 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI DEMBER, LAURA M, FARRAR, JOHN T · 2019 to 2024
$6.6M
Pain Reduction and Opioid MedIcation Safety in ESRD (PROMISE) studyU01DK123812 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI JHAMB, MANISHA, LIEBSCHUTZ, JANE M · 2019 to 2020
$3.1M
University of Illinois at Chicago Hemodialysis Opioid Prescription Effort (HOPE) Clinical CenterU01DK123787 · NIDDK · UNIVERSITY OF ILLINOIS AT CHICAGO · PI DOORENBOS, ARDITH Z, FISCHER, MICHAEL J. · 2019 to 2020
$3.0M
Changes in Oral and Gut Microbiota and Incidence and Severity of Patient-Reported Symptoms in Pre- and Post-Kidney Transplant PatientsK23NR018482 · NINR · UNIVERSITY OF ILLINOIS AT CHICAGO · PI LOCKWOOD, MARK · 2019 to 2021
$486k
NCATS NIH HHS UL1 TR001863NIDDK NIH HHS U01 DK123787NIDDK NIH HHS U01 DK123812NIDDK NIH HHS U01 DK123813NINR NIH HHS K23 NR018482
6 · The paper itself

Abstract

Chronic pain is highly prevalent among adults treated with maintenance haemodialysis (HD) and has profound negative effects. Over four decades, research has demonstrated that 50-80% of adult patients treated with HD report having pain. Half of patients with HD-dependent kidney failure (HDKF) have chronic moderate-to-severe pain, which is similar to the burden of pain in patients with cancer. However, pain management in patients with HDKF is often ineffective as most patients report that their pain is inadequately treated. Opioid analgesics are prescribed more frequently for patients receiving HD than for individuals in the general population with chronic pain, and are associated with increased morbidity, mortality and health-care resource use. Furthermore, current opioid prescribing patterns are frequently inconsistent with guideline-recommended care. Evidence for the effectiveness of opioids in pain management in general, and in patients with HDKF specifically, is lacking. Nonetheless, long-term opioid therapy has a role in the treatment of some patients when used selectively, carefully and combined with an ongoing assessment of risks and benefits. Here, we provide a comprehensive overview of the use of opioid therapy in patients with HDKF and chronic pain, including a discussion of buprenorphine, which has potential as an analgesic option for patients receiving HD owing to its unique pharmacological properties.

Indexed as

Chronic PainRenal InsufficiencyAdultAnalgesics, OpioidHumansPain ManagementPractice Patterns, Physicians'Renal DialysisAnalgesics, Opioid

Identifiers

PMID34621058
PMCPMC8792317
OpenAlexW3204466702

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.